To do so, we selected, among cell lines found to re-express H1.0 upon Quisinostat treatment (Fig. 1d), lines from different cancer types that are known to develop acquired resistance to targeted agents: non-small lung cancer (NSCLC) cells that model resistance to EGFR tyrosine kinase inhibitors (EGFRi) in EGFR-mutated patients (PC9, HCC827 and H1975, cell line 13, 14, 15 in Fig. 1d) and breast cancer cells that develop resistance to the anti-HER2 antibody Trastuzumab (BT474, cell line 16 in Fig. 1d). This evidence concerns the gene EGFR and breast cancer.